Investing.com - Financial Markets Worldwide

Oxford BioMedica PLC (OXB)

London
Currency in GBP
440.50
-2.00(-0.45%)
Closed·

OXB Financial Summary

Key Ratios

P/E Ratio-7.27
Price/Book5.64
Debt / Equity179.81%
Return on Equity-70.28%
Dividend Yield0.00%
EBITDA-20.89M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2015
31/12
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
Income Statement
Total Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa87.73142.8139.9989.54128.8
Gross Profit
aa.aaaa.aaaa.aaaa.aaaa.aa46.0782.6469.1839.7353.02
Operating Income
aa.aaaa.aaaa.aaaa.aaaa.aa-4.8622.13-46.46-85.91-37.81
Net Income
aa.aaaa.aaaa.aaaa.aaaa.aa-6.2519.01-39.16-157.49-43.19
Balance Sheet
Total Assets
aa.aaaa.aaaa.aaaa.aaaa.aa183.93237.23460.18252.34231.64
Total Current Liabilities
aa.aaaa.aaaa.aaaa.aaaa.aa52.4633.3159.6644.3258.32
Total Equity
aa.aaaa.aaaa.aaaa.aaaa.aa112.75187.34236.1977.8360.49
Cash Flow
Levered Free Cash Flow
aa.aaaa.aaaa.aaaa.aaaa.aa-6.8210.88-12.82-17.07-34.85
Cash from Operations
aa.aaaa.aaaa.aaaa.aaaa.aa3.1225.46-12.62-28.52-50.67
Cash from Investing
aa.aaaa.aaaa.aaaa.aaaa.aa-10.8-9.46-56.462.815.63
Cash from Financing
aa.aaaa.aaaa.aaaa.aaaa.aa38.1946.2198.62-12.72.91
Net Change in Cash
aa.aaaa.aaaa.aaaa.aaaa.aa30.562.232.34-37.57-43.07
* In Millions of GBP (except for per share items)

Analyst Ratings

6 Buy
2 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 507.75
(+15.27% Upside)

Earnings

Latest Release
Apr 25, 2025
EPS / Forecast
-0.11 / -0.0784
Revenue / Forecast
77.99M / 77.20M
EPS Revisions
a
a
Unlock
Last 90 days

FAQ

What were Oxford BioMedica's earnings for the latest quarter?

The Oxford BioMedica EPS (TTM) is -0.42. Oxford BioMedica reported sales of 77.99, net income of -10.71, and EPS of -0.11 for the latest quarter.

What was Oxford BioMedica's net income for the latest quarter?

Oxford BioMedica's net income for the latest quarter was -10.71.

How did Oxford BioMedica's performance compare year-over-year in the latest quarter?

The company's revenue moved from 50.81 in the previous quarter to 77.99 in the latest quarter, and net income moved from -32.49 to -10.71 compared to the previous quarter.

What is Oxford BioMedica's net profit margin on a TTM basis?

Oxford BioMedica's trailing twelve months (TTM) net profit margin is -33.53%.

How does Oxford BioMedica's debt to equity ratio compare to industry standards?

Oxford BioMedica's total debt-to-equity ratio is 179.81%.

What is Oxford BioMedica's return on investment on a TTM basis?

Oxford BioMedica's trailing twelve months (TTM) return on investment (ROI) is -70.28%.

Did Oxford BioMedica gain or lose cash last quarter?

In the latest quarter, Oxford BioMedica's net change in cash was -20.76 million.

What were Oxford BioMedica's total assets and liabilities in the latest quarter?

As of the latest quarter, Oxford BioMedica reported total assets of 231.64 million and total liabilities of 58.32 million.

How has Oxford BioMedica's total revenue grown this year?

Oxford BioMedica's total revenue was 50.81 in the previous quarter and 77.99 in the latest quarter.

What is Oxford BioMedica's gross margin on a TTM basis?

Oxford BioMedica's trailing twelve months (TTM) gross margin is 41.17%.

What was Oxford BioMedica's revenue per share for the latest quarter?

Oxford BioMedica's revenue per share for the latest quarter was 11.23.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.